PA
OWL icon

PharVision Advisers’s Blue Owl Capital OWL Stock Holding History

PharVision Advisers’s Portfolio OWL Stock Details OWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,748
Closed -$220K – 494
2025
Q4 		$220K Buy
+14,748
New +$231K 0.11% 479

Other funds holding OWL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LVIA
Lind Value II ApS Aarhus C, Denmark $451M AUM 17.35% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

PharVision Advisers's OWL Position: Q1 2026 in Review

PharVision Advisers sold out of Blue Owl Capital (OWL) in Q1 2026, closing a stake of 14,748 shares — an estimated $220K sold.

PharVision Advisers first reported a position in OWL in Q4 2025 and held it in 1 quarter. The position peaked at $220K in Q4 2025. 544 funds tracked by Wall St. Rank hold OWL as of Q1 2026.

  • PharVision Advisers reported no remaining Blue Owl Capital position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 14,748 Blue Owl Capital shares in Q1 2026, an estimated $220K.
  • PharVision Advisers first reported a position in Blue Owl Capital in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Blue Owl Capital position peaked at $220K in Q4 2025.
  • 544 funds tracked by Wall St. Rank held Blue Owl Capital as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.